PO.CL01.16 · 临床研究

与Barrett食管进展风险相关的持续性免疫微环境改变

Persistent immune microenvironment changes associated with progression risk in Barrett's esophagus

海报缩略图:与Barrett食管进展风险相关的持续性免疫微环境改变
编号 3940 展板 15 时间 4/20 02:00–05:00 区域 Section 48 主讲 Hyun Young Park, MS
分会场 Prognostic Biomarkers 2
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Hyun Young Park1, Erin E. Grayhack1, Ashten Omstead1, Christopher Sherry1, Alisha Khan1, Catherine Lewis1, Neda Dadgar1, Kunhong Xiao1, Gursimran Kochhar1, Michael Landau1, Douglas B. Stairs2, Ali H. Zaidi1, Patrick L. Wagner1

1Allegheny Health Network, Pittsburgh, PA,2Penn State Cancer Institute, Hershey, PA

摘要 Abstract

中文摘要
Barrett食管(BE)是食管腺癌(EAC)的主要危险因素。由于只有少数BE患者进展为高级别异型增生(HGD)或EAC,风险生物标志物需求迫切。我们既往的研究发现了BE患者初诊时固有层淋巴细胞和巨噬细胞亚群相对丰度的改变。在本研究中,我们通过分析这些患者的系列监测样本来扩展这些发现,以评估这些免疫微环境随时间的变化。检查了来自非异型增生性BE患者接受内镜活检的福尔马林固定石蜡包埋组织样本。检查了来自58例独立患者的初诊样本(n=58)和系列监测样本(n=78),其中25例随后被诊断为HGD或EAC(进展者),而33例患者在至少5年的监测期间未进展(非进展者)。使用针对CD3和CD8(淋巴细胞)、CD68/CD86双阳性(M1样)巨噬细胞及CD68/CD206双阳性(M2样)巨噬细胞的特异性抗体进行免疫组化染色。对从BE区域固有层中选取的感兴趣区域(ROI)进行数字图像分析,并采用Welch t检验对进展这一结局进行免疫细胞密度的亚组比较。总计检查了来自非进展者的3540个ROI(1526个初诊,2014个随访)和来自进展者的2994个ROI(1077个初诊,1917个随访)。相对于非进展者,进展者活检中含有显著更高密度的CD3+淋巴细胞(4586 vs 2633,p=0.0019)和显著更低密度的CD8+淋巴细胞(798 vs 1359,p=0.002)。与此同时,进展者中M1样巨噬细胞显著升高(84.7 vs 34.6,p=0.003),而M2样巨噬细胞相对于非进展者显著降低(35.5 vs 80.3,p<0.0001)。该差异在随访活检时持续存在(CD3+:1566 vs 1228,p<0.0001;M1:244 vs 48.4,p<0.0001),而其他免疫细胞发生变化(CD8+:350 vs 396,p=0.096 vs M2:66.5 vs 37.6,p=0.0066)。免疫细胞密度提示BE微环境存在持久性特征。相对于不进展者,注定进展为HGD或EAC的患者,其BE免疫微环境在固有层淋巴细胞和巨噬细胞群方面表现出显著差异。这些我们在此显示可在系列活检中随时间持续存在的发现,值得进一步研究以加深我们对这一改变的免疫微环境的理解,无论是作为进展风险的生物标志物,还是作为免疫调节性预防策略的潜在靶点。
查看英文原文 English abstract
Barrett's esophagus (BE) is the principal risk factor for esophageal adenocarcinoma (EAC). Since only a small number of patients with BE progress to high-grade dysplasia (HGD) or EAC, biomarkers of risk are in high demand. Our previous work identified alterations in the relative abundance of lamina propria lymphocyte and macrophage subsets in BE patients at initial diagnosis. In this study, we extended these findings by analyzing serial surveillance samples from these patients to assess the changes of these immune microenvironments over time. Formalin-fixed, paraffin-embedded tissue samples from patients with non-dysplastic BE undergoing endoscopic biopsy were examined. Initial diagnostic samples (n=58) and serial surveillance samples (n=78) from 58 unique patients were examined, among whom 25 were subsequently diagnosed with HGD or EAC (“progressors”), while 33 patients did not progress during at least 5 years of surveillance (“non-progressors”). Immunohistochemical staining was performed with antibodies specific for CD3 and CD8 (lymphocytes), CD68/CD86 co-positive (“M1- like”) macrophages, and CD68/CD206 co-positive (“M2-like”) macrophages. Regions of interest (ROI) selected from the lamina propria in the region of BE were subjected to digital image analysis, and subgroup comparisons of immune cell densities were carried out using Welch's t-test for the outcome of progression. In total, 3540 ROIs from non-progressors (1526 initial, 2014 follow-up) and 2994 ROIs from progressors (1077 initial, 1917 follow-up) were examined. Relative to non-progressors, progressor biopsies contained a markedly greater density of CD3+ lymphocytes (4586 vs. 2633, p=0.0019) and a significantly lower density of CD8+ lymphocytes (798 vs. 1359, p=0.002). Concomitantly, M1-like macrophages were significantly elevated in progressors (84.7 vs. 34.6, p=0.003), while M2-like macrophages were markedly decreased (35.5 vs. 80.3, p<0.0001) relative to non-progressors. The difference persisted at follow-up biopsy, (CD3+:1566 vs. 1228, p<0.0001; M1: 244 vs. 48.4, p<0.0001), whereas other immune cells changed (CD8+: 350 vs. 396, p=0.096 vs. M2: 66.5 vs 37.6, p=0.0066). The immune cell density suggests that there is an enduring feature of the BE microenvironment.The BE immune microenvironment demonstrates substantial differences in lamina propria lymphocyte and macrophage populations in patients who are destined to progress to HGD or EAC, relative to those who are not. These findings, which we show here to persist in serial biopsies over time, warrant further investigation to deepen our understanding of this altered immune microenvironment, both as a biomarker of progression risk and a potential target for immunomodulatory prevention strategies.
利益披露 Disclosure
H. Park, None.. E. E. Grayhack, None.. A. Omstead, None.. C. Sherry, None.. A. Khan, None.. C. Lewis, None.. N. Dadgar, None.. K. Xiao, None.. G. Kochhar, None.. M. Landau, None.. D. B. Stairs, None.. A. H. Zaidi, None.. P. L. Wagner, None.

← 返回 AACR 2026 检索